SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly earnings beat expectations and its raised outlook, powered by rapid commercial AI growth that surpassed U.S. government revenue for the first time, are driving discussion. Bulls point to strong execution, while bears argue the growth was already priced in and the stocks weak reaction reflects its high valuation and broader tech-market pressure.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples quarterly earnings beat estimates, but shares sold off as traders focused on margin pressure from rising memory costs, slower growth guidance, and weaker China, iPad, and wearables results. The community is split between buyers pointing to strong iPhone sales and bulls arguing the drop is an overreaction, and skeptics concerned about valuation and the outlook.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reached its prespecified 80th event, triggering final analysis and putting the pending GPS topline results in focus. The stocks sharp decline since the milestone has fueled debate over profit-taking and risk reduction ahead of a binary readout versus unsubstantiated claims of manipulation or a data leak; no results have been disclosed.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum is driving attention, with traders criticizing the dilution, price and long closing timeline as the stock sells off. Others argue the deal strengthens Marvells position in AI data-center optical connectivity and could pay off over the longer term.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned equity and debt fundraising for its AI infrastructure buildout has driven the selloff, with traders worried about shareholder dilution, rising leverage, and whether AI spending will pay off. Others argue the financing was already outlined and see the sharp reaction as an overreaction or a buying opportunity.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings report is the focus after a sharp selloff in the shares and broader semiconductor weakness following Intels warning. Traders are divided on whether AI-chip demand and forward guidance can restore confidence or whether high valuation and the recent tech-sector pressure will weigh on the stock despite a strong report.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small-cap rotation and IWMs relative strength against pressured megacap technology stocks dominate the discussion, with traders debating whether the rebound signals a sustained recovery or a temporary bounce. Bulls point to improving small-cap momentum and seasonal optimism, while bears cite choppy trading and uncertainty around interest rates, elections, and geopolitical risks.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA drew attention as the Dow held up better than tech-heavy indexes amid concern over AI spending and valuations, with traders debating whether the markets bounce could last and many continuing to favor shorts. Lower oil on hopes for U.S.-Iran diplomacy also featured in the broader market discussion.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells announced all-stock acquisition of Lumentum is driving attention, with LITE shares plunging as traders focus on the fixed exchange ratio, exposure to Marvells falling share price, and the long wait for closing. Many criticize the deal as unfavorable to LITE shareholders and question whether it will be approved, while others see the selloff as an overreaction and point to the companies AI-optics strategic fit.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergents Q3 results and reduced full-year outlook are driving discussion, with traders focused on weak revenue, declining NARCAN sales and delayed or uncertain government orders. Bears question the turnaround and debt outlook, while bulls point to cost cuts and potential future CYFENDUS replenishment as offsets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?

Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders? Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 21, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)PR NewswireNEW YORK, Sept. 18, 2026 NEW YORK, Sept. 18, 2026 /PRNewswire...

Aethlon Medical Q1 2027 Earnings Call Transcript

Aethlon Medical (NASDAQ:AEMD) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial data andread more...

Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04read more...

Five Companies Enter the Spotlight with Big Catalysts

The small-cap market is heating up with a fresh wave of catalysts, as several companies put major developments in front of investors. Among the names drawing attention are Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), Turbo Energy (NASDAQ:TURB), and Datasea Intelligent Technology (NASDAQ:DTSS).

AEMD Stock Alert: Halper Sadeh LLC is Investigating Whether Aethlon Medical, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Aethlon Medical, Inc. (NASDAQ: AEMD) and North Immunology, Inc. Upon closing of the proposed transaction, Aethlon shareholders are expected to own approximately 4.75% of the combined company.Halper Sadeh encourages...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million.
Akanda (NASDAQ:AKAN) stock rose 15.07% to $3.13.read more...

AEMD’s Radical Reset Puts NOR-101 in the Spotlight

Aethlon Medical (NASDAQ:AEMD) is making a dramatic turn from medical-device developer to clinical-stage immunology company, announcing an all-stock merger with privately held North Immunology alongside an oversubscribed $180 million financing.

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisPR NewswireSAN DIEGO and AUSTIN, Texas, Sept. 17...

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) shares moved upwards byread more...

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.

Aethlon Medical Inc

Why Did Aethlon Medical Stock Tumble Over 12% Today?

Equity

Bullish Sentiment

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 

Vanguard Extended Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$5.29
Prev Close	$5.44
Open	$5.53
Dividend Yield	0.00%
50-Day Moving Average	$4.47
Beta	0.94
Avg. Volume	4.74M
PE Ratio	-0.13

52-Week High	$26.20
52-Week Low	$1.41
Market Capitalization	$8.73M
EPS (Annual)	-$53.06
Price to Book	0.50
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AEMD Fundamentals